Pozitronová emisní tomografie v diagnostice a sledování pacientů s neseminomovými germinálními nádory
[Positron emission tomography in the diagnosis and monitoring of patients with nonseminomatous germ cell tumours]
Language Czech Country Czech Republic Media print
Document type Journal Article, Research Support, Non-U.S. Gov't
PubMed
22257229
PII: 36639
- MeSH
- Fluorodeoxyglucose F18 MeSH
- Neoplasms, Germ Cell and Embryonal diagnostic imaging drug therapy secondary MeSH
- Humans MeSH
- Positron-Emission Tomography * MeSH
- Radiopharmaceuticals MeSH
- Sensitivity and Specificity MeSH
- Testicular Neoplasms diagnostic imaging drug therapy MeSH
- Check Tag
- Humans MeSH
- Male MeSH
- Publication type
- Journal Article MeSH
- Research Support, Non-U.S. Gov't MeSH
- Names of Substances
- Fluorodeoxyglucose F18 MeSH
- Radiopharmaceuticals MeSH
The role of 18-fluorodeoxyglucose positron emission tomography (FDG-PET) in the diagnosis and monitoring of nonseminomatous germ cell tumours is currently unclear. Clinical studies have suggested that FDG-PET has relatively low sensitivity and specificity in the setting of initial staging and viability assessment of post-chemotherapy residual lesions. On the other hand, FDG-PET provides potentially useful information in patients with elevated tumour markers and/or multiple residual lesions with limited resectability. Other possible indications of FDG-PET are the early assessment of tumour chemosensitivity and the diagnosis of inflammatory treatment complications.
